AIM ImmunoTech (AIM) investor relations material

Strategic focus and clinical progress

• Ampligen's development shifted to late-stage pancreatic cancer due to compelling clinical data and significant unmet medical need, with favorable results in both survival and quality of life from early access and ongoing phase II studies.

• The DURIPANC phase II study, in collaboration with AstraZeneca and Erasmus University, is showing positive interim results in safety, disease stabilization, and quality of life, with enrollment expected to complete by mid-2024 and primary endpoint data by year-end.

• Ampligen has received orphan drug designations and patent protection through 2039, providing market exclusivity and enhancing long-term commercial value.

• The company is preparing for a pivotal phase III trial, partnering with Thermo Fisher Scientific’s PPD group for study design, aiming to de-risk execution and support global market entry.

• Data from the current phase II will inform phase III design, with additional mechanistic insights being collected to strengthen regulatory and commercial positioning.

Market opportunity and competitive landscape

• Pancreatic cancer represents a large, underserved market with approximately 150,000 annual deaths across major markets and limited effective therapies.

• Ampligen’s positive impact on survival and quality of life positions it as a potential standard-of-care therapy, not just a niche product.

• Recent advancements by larger competitors like Revolution Medicines validate the sector’s value and highlight the potential for significant market cap growth upon successful phase III results.

• The company’s IP and orphan drug status provide a strong foundation for future licensing or acquisition discussions with major pharmaceutical firms.

• Ampligen’s platform potential extends beyond pancreatic cancer, with promising data in other solid tumors, including ovarian cancer.

Upcoming milestones and financial outlook

• Key milestones in the next 6–12 months include completion of phase II enrollment, mid-year and year-end data reports, and advancing phase III planning.

• Successful phase II outcomes could catalyze value creation through partnerships, licensing, or acquisition, with the company positioned for a potential “payday” for shareholders.

• The company’s strategy is to leverage strong clinical data and exclusivity protections to maximize commercial and shareholder value as it approaches the final stages of the R&D lifecycle.

• Ongoing collaboration with leading institutions and CROs is intended to ensure robust trial execution and global market readiness.

• The leadership emphasizes both the business opportunity and the mission to provide hope and improved outcomes for patients with few alternatives.